Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.Medscape Oncology

Source: Medscape Today Headlines - January 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news